Last €207.40 EUR
Change Today +0.374 / 0.18%
Volume 65.0
AG4 On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 11:01 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2525 Dupont Drive

Irvine, CA 92612

United States

Phone: 714-246-4500

Fax: 714-246-6987

Allergan, Inc., a multi-specialty health care company, focuses on developing and commercializing pharmaceuticals, biologics, medical devices, and over-the-counter products. The company discovers, develops, and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets in approximately 100 countries worldwide. Segments The company operates its business on the basis of two segments, Specialty Pharmaceuticals and Medical Devices. Specialty Pharmaceuticals segment This segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products; and urologics products. Eye Care Pharmaceuticals The company develops, manufactures, and markets a range of prescription and non-prescription products designed to treat diseases and disorders of the eye, including dry eye, glaucoma, inflammation, infection, allergy, and retinal disease. Dry Eye Restasis (cyclosporine ophthalmic emulsion) 0.05% is the company’s primary eye care product. Restasis is approved in approximately 35 countries. The company’s artificial tears products, including the Refresh and Optive product lines of lubricant eye drops, treat dry eye symptoms, including irritation and dryness due to pollution, computer use, aging, and other causes. The company offers Refresh Optive Advanced lubricant eye drops in the United States and Refresh Optive Advanced/Optive Plus is approved in approximately 40 countries. It also offers Refresh Optive Advanced/Optive Plus unit dose, which is approved in approximately 30 countries. In 2014, Optive Fusion was launched in the United Kingdom, Germany, Austria, Poland, Scandinavia, Turkey, and Greece. Optive Plus offers relief for the lipid deficient dry eye sufferer and Optive Fusion addresses the aqueous deficient segment of the dry eye market. Glaucoma The company’s Lumigan (bimatoprost ophthalmic solution) product line is its another primary eye care product line. Lumigan 0.01% is a topical treatment indicated for the reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension. Lumigan 0.01% is approved in Canada, the United States, and Europe. The company sells Lumigan 0.01% in the United States and it is approved in approximately 55 countries worldwide. Lumigan unit dose was approved in Canada in 2013 and the company has completed the introduction of Lumigan unit dose across the European Union. In 2014, the company launched Lumigan unit dose in Australia. Senju Pharmaceutical Co., Ltd. (Senju) is responsible for the development and commercialization of Lumigan in Japan pursuant to a licensing agreement. Ganfort (bimatoprost/timolol maleate ophthalmic solution) is a bimatoprost and timolol maleate combination designed to treat glaucoma and ocular hypertension in patients who are not responsive to treatment with one medication. The company has approval to market Ganfort in the European Union. Ganfort is approved in approximately 70 countries. In 2014, Ganfort was launched in China and Ganfort unit dose was launched in various countries, including Italy, Spain, and Switzerland. The company’s Alphagan (brimonidine tartrate ophthalmic solution) products are its eye care product line. Alphagan P 0.1%, Alphagan P 0.15%, and Alphagan P 0.2% are ophthalmic solutions that lower intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow. Alphagan P 0.1% is approved by the U.S. Food and Drug Administration (FDA) and is an improved reformulation of Alphagan P 0.15%, which is approved by the FDA. Alphagan products are approved in approximately 80 countries. Senju is responsible for the development and commercialization of the company’s Alphagan products in Japan pursuant to a licensing agreement between the company and Kyorin Pharmaceuticals Co., Ltd. (Kyorin) that Kyori

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AG4:GR €207.40 EUR +0.374

AG4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $291.72 USD +1.94
Astellas Pharma Inc ¥1,901 JPY +3.00
Boston Scientific Corp $16.89 USD +0.07
Mylan Inc/PA $58.37 USD +1.13
Regeneron Pharmaceuticals Inc $416.50 USD -3.37
View Industry Companies
 

Industry Analysis

AG4

Industry Average

Valuation AG4 Industry Range
Price/Earnings 46.3x
Price/Sales 9.6x
Price/Book 9.0x
Price/Cash Flow 42.6x
TEV/Sales 8.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN INC, please visit www.allergan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.